Physician profile
Aaron M Perlmutter
NPI 1114952496
$11,842.22
in general payments reported to CMS, 2019-2025
37 companies · $955 in 2025
The $955 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,235 · 2020: $1,447 · 2021: $1,005 · 2022: $1,338 · 2023: $1,281 · 2024: $1,581 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,817.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,180.26 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $3,226.79 | 2019-2025 | Yeztugo |
| Emd Serono, INC. | $603.22 | 2019-2025 | Serostim |
| Janssen Biotech, INC. | $496.15 | 2019-2022 | |
| Napo Pharmaceuticals INC | $401.93 | 2019-2023 | Mytesi |
| Merck Sharp & Dohme LLC | $374.94 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Novo Nordisk INC | $312.65 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $307.09 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.27 | 2019-2025 | Entyvio |
| Amgen INC. | $256.32 | 2019-2020 | |
| Antares Pharma, INC. | $174.52 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $167.98 | 2020-2025 | Lifevest |
| Lilly USA, LLC | $123.03 | 2019-2024 | Zepbound, Mounjaro |
| Theratechnologies INC. | $104.90 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $84.44 | 2023-2024 | Amvuttra |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Perlmutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.